Treatment Patterns of Atopic Dermatitis Medication in 0–10-Year-Olds: A Nationwide Prescription-Based Study

Abstract

Introduction:The literature on treatment patterns for paediatric atopic dermatitis (AD) is scarce and is rarely based on real-world data. Using national registers, we sought to establish up-to-date, population-based prevalence estimates, predictors of risk and disease burden and a comprehensive overview of treatment patterns and course for paediatric patients with AD. Methods: Dispensed prescriptions for the entire Norwegian child population aged 0-10 years from 2014 to 2020 were analysed. Results: There were 176,458 paediatric patients with AD. Of these, 99.2% received topical corticosteroids, 5.1% received topical calcineurin inhibitors, 37.1% received potent topical corticosteroids and 2.1% received systemic corticosteroids. Of the 59,335 live births in Norway (2014), 14,385 [24.8%; 95% confidence interval (CI) 24.5-25.1] paediatric patients were treated

Også allmennleger må få forske

“…Ett eksempel er valideringen av en prehospital algoritme for bruk av troponin T i en allmennmedisinsk populasjon hvor pretest-sannsynlighet for sykdom er lavere enn i en sykehuspopulasjon (4). Andre eksempler er behandling av eksem hos barn, som i stor grad skjer i allmennpraksis (5), og bruk av ibuprofen versus pivmecillinam mot urinveisinfeksjon og risiko for utvikling av pyelonefritt (6). En svaert viktig publikasjon handler om betydningen av et langvarig lege-pasient-forhold og viser at pasienter som har samme fastlege i mer enn femten år, har 25 % lavere risiko for å dø enn pasienter som har hatt samme fastlege i bare ett år eller mindre (7).…”

Metabolic Comorbidities in Pediatric Atopic Dermatitis: A Narrative Review

“…Indeed, some patients do not respond to the standard treatments, so it is necessary to considerer the role of microorganism such as Candida and Malassetia , Dermatophytes and Staphylococcus aureus , which role in aggravating AD is now well documented [ 6 , 7 ]. When the disease becomes severe, the switch to systemic therapy with immunosuppressive agents and/or biologic drugs is required [ 8 ].…”